Last update 10 Jun 2026

Anagliptin/Empagliflozin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Empa-guard, 엠파가드정
Target
DPP-4 x SGLT2
Action
inhibitors
Mechanism
DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors)
Therapeutic Areas
Endocrinology and Metabolic Disease
Active Indication
Diabetes Mellitus, Type 2
Inactive Indication-
Originator Organization
JW PHARMACEUTICAL Corp.JW PHARMACEUTICAL Corp.
Active Organization
JW PHARMACEUTICAL Corp.JW PHARMACEUTICAL Corp.
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
South Korea (11 May 2026),
Diabetes Mellitus, Type 2
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC19H25N7O2
InChIKeyLDXYBEHACFJIEL-HNNXBMFYSA-N
CAS Registry739366-20-2
View All Structures (2)

Related

100 Clinical Results associated with Anagliptin/Empagliflozin
Login to view more data
100 Translational Medicine associated with Anagliptin/Empagliflozin
Login to view more data
100 Patents (Medical) associated with Anagliptin/Empagliflozin
Login to view more data
100 Deals associated with Anagliptin/Empagliflozin
Login to view more data

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
South Korea
JW PHARMACEUTICAL Corp.JW PHARMACEUTICAL Corp.
11 May 2026
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free